| Tyyppi : |
Lehti |
|
| Tutkimus Joukkueet : |
Vancouver - Children\'s and Women\'s Health Center of British Columbia |
| Tekijät : |
Ensom MHH, Decarie D, Sheppard I. |
| Otsikko : |
Stability of lansoprazole in extemporaneously compounded suspensions for nasogastric or oral administration. |
| Numero : |
Can J Hosp Pharm ; 60, 3: 184-191. 2007 |
|
| Todisteiden määrä : |
|
| Fyysinen vakaus : |
|
| Kemiallinen stabiilisuus : |
|
| Muut menetelmät : |
|
| Commentairesvaleur : |
|
Luettelo yhdisteistä
 Lansoprazole
|
 |
 |
 |
 |
150 mg
®=? (Abbott Laboratories) |
|
25°C |
 |
| 91 |
 |
|
|
|
|
|
150 mg
®=? (Abbott Laboratories) |
| NaHCO3 8,4 % |
25 ml |
| NaOH |
1N = 1.7 ml |
| OraPlus® / OraSweet® (1:1) |
23.3 ml |
| PH= |
8.4 |
|
25°C |
|
| 91 |
|
|
|
|
|
|
150 mg
®=? (Abbott Laboratories) |
|
4°C |
 |
| 91 |
|
|
|
|
|
|
150 mg
®=? (Abbott Laboratories) |
| NaHCO3 8,4 % |
25 ml |
| NaOH |
1N = 1.7 ml |
| OraPlus® / OraSweet® (1:1) |
23.3 ml |
| PH= |
8.4 |
|
4°C |
|
| 91 |
|
|
|
|
|
